Combined scleral buckle and BGI is effective

Article

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment.

Combined scleral buckle and Baerveldt glaucoma implantation (BGI) is effective for managing coexisting glaucoma and retinal detachment, while minimizing surgical risk, states a journal paper.

Professor V.C. Lima et al., Department of Ophthalmology and Einhorn Clinical Research Center, The New York Eye and Ear Infirmary, New York, USA, included 30 eyes of 30 patients in a retrospective, consecutive, noncomparative, interventional case series.

All patients underwent simultaneous scleral and BGI surgery and were separated into a staged BGI group of 21 patients and a non-staged BGI group consisting of 9 patients. Successful IOP control was identified as 6 mmHg ≤ IOP ≤ 18 mmHg.

Mean best-corrected visual acuity improved from 2.0 preoperatively to 1.7 postoperatively. In the staged group 62% required second-stage tube insertion postoperatively. Mean IOP was reduced from 31.1±10.8 to 12.7±6.0 mmHg, mean number of glaucoma medications was lowered from 2.9±1.4 to 1.2±1.3.

Combined scleral buckle and BGI is a successful management technique for coexisting glaucoma and retinal detachment and greatly reduces surgical risk.

Please visit the Journal of Glaucoma for more information.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.